small molecule

MAXALT

RIZATRIPTAN BENZOATE

Loss of exclusivity—loss of exclusivity

CompanyOrganon →See this company's full patent-cliff portfolio

Drug detail

Brand name	MAXALT
Active ingredient	RIZATRIPTAN BENZOATE
Strength	EQ 5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	June 1998
Marketing status	DISCN

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.